Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» CPI-613
CPI-613
Rafael Pharmaceuticals’ Cancer Metabolism Drug Fails Phase III Assessment
BioSpace
Fri, 10/29/21 - 10:59 am
Rafeal Pharmaceuticals
clinical trials
CPI-613
devimistat
cancer